Market Place
Sourcing Support
CG Oncology Reveals 2025 Financials And Business Updates
27 Feb 2026 //
GLOBENEWSWIRE
CG Oncology To Present At TD Cowen Health Care Conference
23 Feb 2026 //
GLOBENEWSWIRE
CG Oncology Announces New Board Member And Board Transition
26 Nov 2025 //
GLOBENEWSWIRE
CG Oncology Reveals Q3 2025 Financials & Business Updates
14 Nov 2025 //
GLOBENEWSWIRE
CG Oncology Executives to Join Investor Conferences
29 Aug 2025 //
GLOBENEWSWIRE
CG Oncology Owes No Future Royalties to ANI Pharmaceuticals
29 Jul 2025 //
GLOBENEWSWIRE
CG Oncology to Join Goldman Sachs 46th Annual Healthcare Conf.
05 Jun 2025 //
GLOBENEWSWIRE
CG Oncology to Join 2025 RBC Capital Market Healthcare Conference
15 May 2025 //
GLOBENEWSWIRE
CG Oncology Reports Q1 2025 Financial Results and Business Update
13 May 2025 //
GLOBENEWSWIRE
SUO-CTC & CG Oncology Announce 2025 NMIBC Research Fellowship Award
01 May 2025 //
GLOBENEWSWIRE
CG Oncology to Host Conference Call on BOND-003 Data on April 28
24 Apr 2025 //
GLOBENEWSWIRE
CG Oncology to Present at 120th AUA Annual Meeting with Updates
31 Mar 2025 //
GLOBENEWSWIRE
CG Oncology To Present At 40th European Urology Congress
12 Mar 2025 //
GLOBENEWSWIRE
CG Oncology to Present at TD Cowen Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
CG Oncology Closes Public Offering, Full Underwriter Option
16 Dec 2024 //
GLOBENEWSWIRE
CG Oncology Announces Pricing of Public Offering
12 Dec 2024 //
GLOBENEWSWIRE
CG Oncology Announces Proposed Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
Cretostimogene Grenadenorepvec Shows Durable Responses in Cancer
05 Dec 2024 //
GLOBENEWSWIRE
CG Oncology Reports Q3 2024 Financial Results & Business Updates
12 Nov 2024 //
GLOBENEWSWIRE
CG Oncology To Attend Morgan Stanley Global Healthcare Conference
30 Aug 2024 //
GLOBENEWSWIRE
CG Oncology Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
CG Oncology Q1 2024 Financials And Business Updates
09 May 2024 //
GLOBENEWSWIRE
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 Apr 2024 //
GLOBENEWSWIRE
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
28 Mar 2024 //
GLOBENEWSWIRE
CG Oncology Announces Closing of Initial Public Offering to Purchase Shares
30 Jan 2024 //
BUSINESSWIRE
CG Oncology Announces Pricing of Upsized Initial Public Offering
24 Jan 2024 //
BUSINESSWIRE
CG Oncology Announces Key Executive Appointments in Commercialization
05 Sep 2023 //
BUSINESSWIRE
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study
24 Jul 2023 //
BUSINESSWIRE
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
27 Dec 2022 //
BUSINESSWIRE
CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA®
10 Nov 2022 //
BUSINESSWIRE
CG spotlights oncolytic virus combo data ahead of full readout due next year
10 Nov 2022 //
ENDPTS
CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA
24 Oct 2022 //
BUSINESSWIRE
CG Oncology Presents New Clinical Data on Two Ongoing Programs at ASCO 2022
04 Jun 2022 //
BUSINESSWIRE
CG Oncology Presents Interim Phase 2 Data with CG0070 + KEYTRUDA
13 Apr 2022 //
BUSINESSWIRE
CG Oncology Begins Dosing in Japan in Phase 3 Monotherapy Study of CG0070
20 Dec 2021 //
BUSINESSWIRE
CG Oncology reports Phase II preliminary data on bladder cancer therapy
15 Nov 2021 //
CLINICALTRIALSARENA
CG Oncology Presents Preliminary Ph 2 Data with CG0070 in Combination KEYTRUDA
13 Nov 2021 //
BUSINESSWIRE
CG Oncology to Present Two Programs atSITC) 2021 Annual Meeting
12 Oct 2021 //
BUSINESSWIRE
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb
09 Sep 2021 //
BUSINESSWIRE
CG Oncology doses first patient in oncolytic immunotherapy trial
10 Dec 2020 //
CLINICALTRIALSARENA
CG Oncology Closes $47 Million Series D Financing
10 Dec 2020 //
BUSINESSWIRE
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070
09 Dec 2020 //
BUSINESSWIRE
CG Oncology Announces First Patient Dosed in Ph1b Study of Oncolytic CG0070
12 Nov 2020 //
BUSINESSWIRE
